Transcriptional repressor of genes that require a bHLH protein for their transcription. May act as a negative regulator of myogenesis by inhibiting the functions of MYOD1 and ASH1. Binds DNA on N-box motifs: 5'-CACNAG-3' with high affinity and on E-box motifs: 5'-CANNTG-3' with low affinity. May play a role in a functional FA core complex response to DNA cross-link damage, being required for the stability and nuclear localization of FA core complex proteins, as well as for FANCD2 monoubiquitination in response to DNA damage. Note: This description may include information from UniProtKB.
Protein type: Cell development/differentiation; Motility/polarity/chemotaxis; Transcription factor
Molecular Function: DNA binding; histone deacetylase binding; protein binding; protein homodimerization activity; sequence-specific DNA binding; transcription factor activity
Biological Process: artery morphogenesis; negative regulation of oligodendrocyte differentiation; negative regulation of transcription from RNA polymerase II promoter; negative regulation of transcription, DNA-dependent; nervous system development; Notch signaling pathway; positive regulation of astrocyte differentiation; positive regulation of cell proliferation; positive regulation of DNA binding; positive regulation of JAK-STAT cascade; positive regulation of mitotic cell cycle, embryonic; positive regulation of transcription from RNA polymerase II promoter; positive regulation of tyrosine phosphorylation of Stat3 protein; protein complex assembly; radial glial cell differentiation in the forebrain; STAT protein nuclear translocation; thymus development
Alt. Names/Synonyms: BHLHB39; Class B basic helix-loop-helix protein 39; FLJ20408; Hairy and enhancer of split 1; hairy and enhancer of split 1, (Drosophila); Hairy homolog; Hairy-like protein; HES-1; HES1; hHL; HL; HRY; Transcription factor HES-1
LTP: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.